W1291 Adalimumab in the Prevention of Postoperative Recurrence of Crohn's Disease

Fernández-Blanco, Ignacio; Monturiol, J; Martinez, B. Gutierrez; Cuite, Cara L.; Taxonera, Carlos

doi:10.1016/s0016-5085(10)63182-4

Cited by 14 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 In a study including 20 patients treated with adalimumab postoperatively, a recurrence rate of 10% (2 patients) 1 year after surgery was reported. 16 Very recently published 6-month data on thiopurine versus adalimumab in 74 high risk patients after ICR 6.2% of patients on adalimumab showed endoscopic recurrence (compared with 38% in the thiopurine group, P ¼ 0.024). 17 However, again, there were no data on surgical recurrence.…”

mentioning

confidence: 98%

Risk Factors for Repetitive Ileocolic Resection in Patients with Crohnʼs Disease

Manser

Frei

Grandinetti

et al. 2014

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 98%

Risk Factors for Repetitive Ileocolic Resection in Patients with Crohnʼs Disease

Manser

Frei

Grandinetti

et al. 2014

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…To date, five studies have been pub lished as full articles and three in a preliminary form. [83][84][85][86][87][88][89][90] Yoshida et al 83 randomly assigned 31 patients (mostly at high risk of recurrence) who were on an elemental diet and mesalazine 4 weeks after surgery to receive either infliximab every 8 weeks (15 patients) or no additional therapy (16 patients). At 1 year, patients treated with infliximab were in clinical, endoscopic and serological remission in 100%, 78.6% and 86.7% of cases, respectively, versus 68.8%, 18.8% and 37.5% in the control group.…”

Section: Preventive Strategiesmentioning

confidence: 99%

“…86 Other studies have shown similar protection rates with adalimumab of 80-100% for endoscopic recurrence and 86-100% for clinical recurrence. [87][88][89][90] Although most of these studies are individually small, uncontrolled and single centre, the total number of patients treated with antiTNF agents for this indi cation is >100 with average global protection rates for e ndoscopic and clinical recurrence of ≥85-90%. 5,80,83-90…”

Section: Preventive Strategiesmentioning

confidence: 99%

State-of-the-art medical prevention of postoperative recurrence of Crohn's disease

Sorrentino

2013

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

Postoperative recurrence of Crohn's disease is a frequent and often severe sequela of the disease. Until a few years ago it was deemed inescapable, as all the conventional medications used to treat the disease have been proven of little benefit in preventing recurrence after surgical treatment. In the past few years, anti-TNF agents given immediately after surgery have shown a remarkable efficacy in the prevention of disease recurrence. Large, randomized, controlled trials are currently underway to confirm these findings. Anti-TNF treatment of endoscopic lesions that occur after surgery seems to be less effective than using TNF antagonists to prevent recurrence. However, although the data are limited, this treatment strategy seems to be still superior to all the other prevention strategies that are not based on anti-TNF agents. Limited data are available on long-term outcomes of patients treated with anti-TNF agents after surgery. They suggest that these medications are safe and effective after many years of treatment. In addition, these agents might prevent recurrence even at doses lower than those used in patients with Crohn's disease who have not had surgery.

show abstract

“…The first case series that evaluated the efficacy of ADA in preventing PER was completed in Spain 20 and published in 2010. In an open-label prospective study, the authors started ADA therapy in 20 patients following ileocolic resection for CD.…”

Section: Adalimumab In the Prevention Of Postoperative Endoscopic Recmentioning

confidence: 99%

Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?

Kotze

Saad-Hossne

2013

Intest Res

View full text Add to dashboard Cite

wide, even with the currently available best medical therapy.Postoperative endoscopic recurrence (PER) after abdominal resection for CD occurs in nearly 75% of patients 1 year after the surgical procedure. 4,5 It develops earlier than clinical recurrence and, most commonly, years before the need for a repeated resection. Several studies have demonstrated the effect of different medications aimed at reducing PER rates. Probiotics and aminosalicylates have not been effective in this scenario.6 Metronidazole and ornidazole were more effective than placebo in 2 randomized controlled trials, but only in a 3-month period.7 Azathioprine was also more effective than placebo and aminosalicylates in preventing PER. 6,8 However, even with these therapies, a significant number of patients developed recurrence and disease progression over time.Biological agents seem proportionally more effective than conventional therapy in preventing PER in various studies. Since the initial trial published in 2009 by Regueiro et al.,9 various authors have studied the effect of both infliximab (IFX) and adalimumab (ADA) in reducing PER rates or treating

show abstract

W1291 Adalimumab in the Prevention of Postoperative Recurrence of Crohn's Disease

Cited by 14 publications

References 0 publications

Risk Factors for Repetitive Ileocolic Resection in Patients with Crohnʼs Disease

Risk Factors for Repetitive Ileocolic Resection in Patients with Crohnʼs Disease

State-of-the-art medical prevention of postoperative recurrence of Crohn's disease

Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?

Contact Info

Product

Resources

About